Drugs for Hypertension
May 27, 2024 (Issue: 1703)
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
- PK Whelton et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 2018; 71:2199. doi:10.1016/j.jacc.2017.11.005
- FM Sacks et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344:3. doi:10.1056/nejm200101043440101
- D Mozaffarian et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014; 371:624. doi:10.1056/nejmoa1304127
- M Roerecke et al. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2017; 2:e108. doi:10.1016/s2468-2667(17)30003-8
- VA Cornelissen et al. Endurance exercise beneficially affects ambulatory blood pressure: a systematic review and meta-analysis. J Hypertens 2013; 31:639. doi:10.1097/hjh.0b013e32835ca964
- JD Inder et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis to optimize benefit. Hypertens Res 2016; 39:88. doi:10.1038/hr.2015.111
- J Poorolajal et al. Oral potassium supplementation for management of essential hypertension: a meta-analysis of randomized controlled trials. PLoS One 2017; 12:e0174967. doi:10.1371/journal.pone.0174967
- Y-C Tsai et al. Effectiveness of salt substitute on cardiovascular outcomes: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2022; 24:1147. doi:10.1111/jch.14562
- JE Neter et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42:878. doi:10.1161/01.hyp.0000094221.86888.ae
- S Salehin et al. Renal denervation in the management of resistant hypertension: a comprehensive review of literature. Curr Probl Cardiol 2024; 49:102137. doi:10.1016/j.cpcardiol.2023.102137
- JT Wright Jr et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169:832. doi:10.1001/archinternmed.2009.60
- RHG Olde Engberink et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension 2015; 65:1033. doi:10.1161/hypertensionaha.114.05122
- G Hripcsak et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020; 180:542. doi:10.1001/jamainternmed.2019.7454
- A Ishani et al. Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med 2022; 387:2401. doi:10.1056/nejmoa2212270
- Sulfonamide cross-reactivity. Med Lett Drugs Ther 2019; 61:44.
- C Chen et al. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis. Medicine (Baltimore) 2020; 99:e21694. doi:10.1097/md.0000000000021694
- DA Calhoun and WB White. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2:462. doi:10.1016/j.jash.2008.05.005
- Drugs for chronic heart failure. Med Lett Drugs Ther 2021; 63:89.
- K Jamerson et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417. doi:10.1056/nejmoa0806182
- G Mancia et al. 2023 ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023; 41:1874. doi:10.1097/hjh.0000000000003480
- CS Wiysonge et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2017; 1:CD002003. doi:10.1002/14651858. cd002003.pub5
- ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283:1967. doi:10.1001/jama.283.15.1967
- EM Krieger et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment). Hypertension 2018; 71:681. doi:10.1161/hypertensionaha.117.10662
- American Society of Health-System Pharmacists. Current drug shortages. Available at: https://bit.ly/3Qs7ETT. Accessed May 9, 2024.
- MP Schlaich et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022; 400:1927. doi:10.1016/s0140-6736(22)02034-7
- Aprocitentan (Tryvio) for treatment-resistant hypertension. Med Lett Drugs Ther 2024 (in press).
- MY Yakoob et al. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. Hypertension 2013; 62:375. doi:10.1161/hypertensionaha.111.00833
- L Duan et al. Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens (Greenwich) 2018; 20:1603. doi:10.1111/jch.13397
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
